GAINESVILLE, Fla., June 03, 2015 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, today announced it has raised $833K in a Series A round through an angel investment fund. Fountainhead Investment Partners, a healthcare angel investment fund, led the round and is working closely with AmnioLife to structure strategic partnerships with medical device companies.
AmnioLife is using the proceeds to support its core manufacturing operations at its Gainesville, FL facility. The Company participated in an IRB-approved study in 2014 that allowed it to validate collection methods of human placental tissue and amniotic fluid, and is working toward vertical integration of its supply chain.
Chris Broderick, CEO, said, "This round of funding is allowing us to implement and validate a GxP-compliant enterprise management software to allow for scalable manufacturing and private branding among our other initiatives and to also conduct a series of safety and preclinical studies on our products that we have developed. We are very much looking forward to our strategic partnership with Fountainhead as their fund partners have significant expertise in medical device commercialization and national distribution of human tissue biologics."
AmnioLife is a research and development organization focused on placental-derived technologies and is building a GxP manufacturing program at its Gainesville, FL facility. The Company aims to commercialize a suite of minimally manipulated tissue products, establish global sales channel partners, and develop a strong IP-position for advanced biologic products. For more information, visit our website at http://www.amniolife.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws that are forward-looking, and based on the current expectations and beliefs of AmnioLife's management team. The forward-looking statements contained in this press release are subject to a number of factors and uncertainties that could cause actual results to differ materially. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and marketplace requirements; delays or obstacles in launching and/or successfully completing some of the clinical study initiatives; products may not be approved by regulatory agencies or regulations may change affecting desired results; inability to retain or attract key employees whose knowledge is essential to the development of required technologies and products; unforeseen scientific difficulties may develop with our process; our patent(s) may not be sufficient; inability to timely develop and introduce new technologies; inability to obtain additional funding; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of AmnioLife to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, AmnioLife disclaims any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.